Asklepios BioPharmaceutical, based on work by UNC Chapel Hill professors Jude Samulski and Xiao Xiao, has secured $235m in funding co-led by TPG Capital and Vida Ventures.
Asklepios BioPharmaceutical (AskBio), a US-based gene therapy spinout of University of North Carolina (UNC) at Chapel Hill, has raised $235m in funding from investors co-led by TPG Capital and Vida Ventures.
TPG and Vida provided a combined $225m, with the remaining $10m supplied by the company’s co-founders and board members.
Founded in 2001, AskBio is working on treatments for rare genetic disorders. The spinout’s approach exploits adeno-associated virus gene therapy and a cell line manufacturing process called Pro10.
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
